., p-aminosalicylic acid); or, it may have toxic side-effects (e.g., cycloserine); or it may be effective, but unavailable in many developing countries (e.g., fluoroquinolones):[citation needed] * aminoglycosides (WHO group 2): e.g., amikacin (AMK), kanamycin (KM); * polypeptides (WHO group 2): e.g., capreomycin, viomycin, enviomycin; * fluoroquinolones (WHO group 3): e.g., ciprofloxacin (CIP
Drug: Background Regimen (BR)Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid
: Aminoglycoside antibiotic agents (streptomycin sulfate, kanamycin sulfate, gentamicin sulfate, neomycin sulfate, spectinomycin hydrochloride, etc.), polypeptides (polymyxin B sulfate), lincomycins (lincomycin hydrochloride, clindamycin), and enviomycin sulfate within 1 week of screening. * Subjects who was diagnosed as having a malignant tumor, or have a history of a malignant tumor within the last 5 years